| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |